» Articles » PMID: 15962522

Azacitidine

Overview
Specialty Pharmacology
Date 2005 Jun 21
PMID 15962522
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status. It is also a pioneering example of an agent that targets 'epigenetic' gene silencing, a mechanism that is exploited by cancer cells to inhibit the expression of genes that counteract the malignant phenotype.

Citing Articles

Epigenetics-targeted drugs: current paradigms and future challenges.

Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S Signal Transduct Target Ther. 2024; 9(1):332.

PMID: 39592582 PMC: 11627502. DOI: 10.1038/s41392-024-02039-0.


Epigenetic regulation of human FOXP3+ Tregs: from homeostasis maintenance to pathogen defense.

Yue Y, Ren Y, Lu C, Li P, Zhang G Front Immunol. 2024; 15:1444533.

PMID: 39144146 PMC: 11323565. DOI: 10.3389/fimmu.2024.1444533.


Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase.

Jeyaraju D, Alapa M, Polonskaia A, Risueno A, Subramanyam P, Anand A Haematologica. 2023; 109(4):1082-1094.

PMID: 37941406 PMC: 10985425. DOI: 10.3324/haematol.2023.283437.


Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes.

Yang Y, Li J, Geng Y, Liu L, Li D J Clin Lab Anal. 2020; 35(2):e23597.

PMID: 33080073 PMC: 7891504. DOI: 10.1002/jcla.23597.


[Progress of Epigenetic Methylation in Lung Cancer Research].

Zhang S, Xue Z Zhongguo Fei Ai Za Zhi. 2017; 20(9):635-640.

PMID: 28935018 PMC: 5973367. DOI: 10.3779/j.issn.1009-3419.2017.09.08.